Progress in research on the effects of different glucagon-like peptide-1 receptor agonists on bone metabolism

doi:10.12092/j.issn.1009-2501.2022.11.015

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (11): 1315-1320.doi: 10.12092/j.issn.1009-2501.2022.11.015

Previous Articles Next Articles

Progress in research on the effects of different glucagon-like peptide-1 receptor agonists on bone metabolism

LI Lingling1,2, ZHANG Yangyang1,2, BAI Jia1,2, YANG Hong1,2, YANG Ying1,2, LV Haihong2

1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, Gansu, China; 2Department of Endocrinology, the First Hospital of Lanzhou University, Lanzhou 730000, Gansu, China

Received:2022-07-01 Revised:2022-11-18 Online:2022-11-26 Published:2022-12-12

Abstract

Abstract: Osteoporosis is one of the common complications of type 2 diabetes mellitus (T2DM). Recent studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can promote bone formation and inhibit bone resorption, suggesting that this hypoglycemic drugs may benefit T2DM patients with osteoporosis and high fracture risk, but its underlying mechanism is not fully understood, and different GLP-1RAs exhibit different skeletal effects and molecular mechanisms. In this paper, the effects of several GLP-1RAs on bone metabolism are reviewed.

Key words: glucagon-like peptide-1 receptor agonists, diabetes, bone metabolism, fracture risk

CLC Number:

R587.1

LI Lingling, ZHANG Yangyang, BAI Jia, YANG Hong, YANG Ying, LV Haihong. Progress in research on the effects of different glucagon-like peptide-1 receptor agonists on bone metabolism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1315-1320.

[1]	MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026.
[2]	MA Xiankang, YANG Lixia, CUI Yangyang, MI Denghai. Angelica polysaccharides improve hepatic endoplasmic reticulum stress by inhibiting the expression of GRP78, p-PERK and p-Eif2α in diabetic KK-Ay mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 926-936.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[5]	ZHANG Xuejiao, LIU Jieting, LI Luxin, CHEN Peijian, DING Minglu, SUN Mengwei, CHU Yanhui, ZHANG Zhen . Effects and mechanism of dapagliflozin on myocardial injury in type 1 diabetes mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 257-265.
[6]	ZHAO Shifeng, SONG Xiangming, YAO Jianping. Tirzepatide: A new glucagon-like peptide-1 receptor/glucose-dependent insulinotropic peptide receptor dual agonist [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 220-227.
[7]	DU Xiaoyu, LI Yumeng, WU Huizhen, QIU Bo. Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1177-1183.
[8]	CAI Jing, PAN Binjing, LIU Jingfang. Research progress on the relationship between hypoglycemic drugs and sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 101-108.
[9]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[10]	LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807.
[11]	ZENG Xiaofan, XU Yiqi, LIU Shu, WU Qian, LI Zibao, HE Junjun, JIN Yuelong, ZHAO Yongli, HE Chunling, GAO Jialin. Retrospectively analysis of the effect of low-dose aspirin on primary prevention of non-fatal myocardial infarction and cerebral infarction in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 665-671.
[12]	LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu. FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
[13]	SHAO Xi, YU Yanan, HUANG Yuhan, WANG Xiaotong, LING Hongwei, LV Dongmei, WANG Tao. Predictive factors associated with weight response to exenatide in patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 287-294.
[14]	DU Chen, TIAN He, CAO Yang, WANG Yongjun, ZHANG Yan. Research progress on bone metabolism disorders associated with PCOS elucidated from endocrine hormones [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 328-333.
[15]	LV Xiaohan, LIN Rong. Association of Lin28 with tumor, cardiovascular disease and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 205-211.

Progress in research on the effects of different glucagon-like peptide-1 receptor agonists on bone metabolism

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments